News – Page 1149 – Endpoints News

SIGN UP

Adaptimmune surges after FDA lifts partial hold; Anthera tanks on PhIII flop; Kadmon axes staffers in restructuring

9 years ago

Bristol-Myers scores fresh bragging rights with PhIII gastric cancer success for Opdivo

9 years ago

Bristol-Myers hands over $100M in cash for a new fibrosis drug, beefing up NASH focus

9 years ago

Cell Medica signs up for an off-the-shelf CAR-T collaboration with Baylor

9 years ago

AstraZeneca axes another R&D track on durvalumab after once again falling behind rivals

9 years ago

Crushed by a PhIII flop, Novavax slashes jobs as it looks to chop out up to $100M in costs

9 years ago

Celgene EVP Rich Bagger makes Politico’s short list for Trump’s Cabinet

9 years ago

Bristol-Myer's Opdivo teams up with Infinity's last hope

9 years ago

Kite gives itself a little more time to finish FDA application for KTE-C19

9 years ago

Biopharma shares rally as Donald Trump scores a stunning upset

9 years ago

As election storm gathered, Arrowhead drops word about a clinical hold

9 years ago

Prop 61 goes down in flames, torching a national drug price control model

9 years ago

CureVac grabs a $29.5M round to fuel its mRNA development efforts

9 years ago

Can AI accelerate drug R&D? J&J offers up some molecules to try it on

9 years ago

Stanford team preps first human CRISPR study for sickle cell disease cure; Shkreli fingers his former attorneys

9 years ago

Versant’s global biotech team is reloading with $350M-plus fund

9 years ago

Cardio event forces FDA to halt a Penn PhII study for multiple myeloma

9 years ago

It’s Endpoints News' issue #100: The new daily biotech pub now has a little history

9 years ago

Cardio drug at The Medicines Co gets the heave-ho. (But they prefer PCSK9 anyway.)

9 years ago

Therapix Bio in the hunt for $12M micro IPO; Progenics bags $50M loan; Juno isn't going anywhere, for now

9 years ago

Roche flags early success for Tecentriq combos, hustles into PhIIIs

9 years ago

Public combat over US drug prices centers on Prop 61 as rhetoric heats up to fever pitch

9 years ago

Poised to launch a new drug for SMA, Biogen and Ionis shares jump on more promising PhIII data

9 years ago

Syncona, CRUK and BACIT join forces to create a $1.2B biotech investment powerhouse

9 years ago

First page Previous page 1146 1147 114811491150 1151 1152 Next page Last page